GlassScriptPhysician profile
Maysoon Hamed
NPI 1881984235
$1,358.13
in general payments reported to CMS, 2019-2025
26 companies · $480 in 2025
The $480 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $370 · 2020: $65.32 · 2024: $443 · 2025: $480.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $922.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $922.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $392.74 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $153.56 | 2019-2020 | |
| Amgen INC. | $80.39 | 2024-2025 | Repatha, Otezla, Tezspire |
| Pfizer INC. | $69.99 | 2019-2020 | |
| Galderma Laboratories, L.P. | $66.97 | 2025 | |
| Exact Sciences Corporation | $66.59 | 2025 | Cologuard Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $63.21 | 2019 | |
| Edwards Lifesciences Corporation | $54.25 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $34.68 | 2024-2025 | Zerbaxa, Dificid |
| Novartis Pharmaceuticals Corporation | $32.92 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $30.47 | 2024 | Airsupra |
| Shire North American Group INC | $27.83 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $26.57 | 2025 | Dupixent |
| Kyowa Kirin, INC. | $26.03 | 2024 | Crysvita |
| Inari Medical, INC. | $25.39 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $24.86 | 2024 | Senza |
| Melinta Therapeutics, LLC | $24.59 | 2019 | |
| Inspire Medical Systems, INC. | $23.94 | 2025 | Inspire |
| Astellas Pharma US INC | $23.35 | 2019 | |
| Dexcom, INC. | $22.93 | 2024 | Dexcom G6 Transmitter |
| Sumitomo Pharma America, INC. | $18.76 | 2025 | Myfembree |
| Philips North America LLC | $15.33 | 2024 | (Ak6) Vest Therapy |
| Novo Nordisk INC | $14.22 | 2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $13.81 | 2024 | Arexvy, Shingrix |
| Mayne Pharma Commercial LLC | $12.41 | 2025 | |
| Biomerieux INC | $12.34 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maysoon Hamed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.